摘要
目的探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法将68例精神分裂症患者随机分为研究组36例,对照组32例,分别给予阿立哌唑及利培酮治疗,疗程8 w。采用简明精神病评定量表、阴性症状量表、大体评定量表评定临床疗效,副反应量表评定不良反应。结果研究组总有效率84%,对照组92%,两组总体疗效相当(P>0.05)。两组各时点简明精神病量表、阴性症状量表评分均较治疗前显著下降(P<0.05或0.01)。研究组治疗第1 w、2 w、4 w末思维障碍、激活性、敌对猜疑、注意障碍等因子分较对照组下降显著(P<0.05或0.01)。研究组用药初期主要不良反应为嗜睡,头晕、头痛、胃肠道反应,1 w后可自行缓解或消失。结论阿立哌唑治疗精神分裂症疗效与利培酮相当,但起效更快。
Objective To explore the clinical efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia. Methods 68 schizophrenics were divided into research group（n=36） taking aripiprazole and control group（n =32） taking risperidone for 8 weeks. Curative effects were assessed with the BPRS,SANS and GAS, and adverse effects with the TESS. Results Total effective rates were 84% of the research group and 92% of the control group respec-tively, global efficacies of the 2 groups were equivalent（P^0.05）. Time-point scores of the BPRS and SANS for both groups decreased significantly compared with pre-treatment（P〈0.05 or 0.01）. In the research group, factors＇ score such as thinking disturbance, activity, hostility-suspicion and disturbance of attention decreased notably at the ends of the 1st, 2nd and 4th week compared with the control group （P〈0.05 or 0.01）. Main adverse effects in the research group were drowsiness, dizzy, headache and gastrointestinal reactions in the initial stage of medication which relieved or disappeared voluntarily in one week. Conclusion Aripiprazolein has equivalent efficacy to risperidone in the treatment of schizophrenia and takes effect faster.
出处
《临床心身疾病杂志》
CAS
2007年第1期7-10,共4页
Journal of Clinical Psychosomatic Diseases
